Initially driven towards treatment of ER+ breast tumors, where up to 40% of ER+ HER-present with mutations in PIK3CA (Vasan et al., 2014), these therapies may also be promising particularly for TNBC for which there are fewer targeted therapies; however, given inconsistent results the clinical development of this drug has been discontinued (Janku et al., 2018). This evidence concerns the gene PIK3CA and breast neoplasm.